Hepatic steatosis and fibrosis: Non-invasive assessment

World Journal of Gastroenterology

Volumn 22, Issue 45, 2016, Pages 9880-9897

  Karanjia, Rustam N ^a   Crossey, Mary M E ^a   Cox, I Jane ^b,c   Fye, Haddy K S ^d   Njie, Ramou ^d   Goldin, Robert D ^a   Taylor Robinson, Simon D ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF HEPATOLOGY   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d MRC The Gambia   (Gambia)

Author keywords

Blood biomarker; Fibrosis; Hepatic steatosis; Non invasive assessment; Ultrasound

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ACOUSTIC RADIATION FORCE IMPULSE IMAGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AST TO PLATELET RATIO INDEX; BILIRUBIN BLOOD LEVEL; BYSTANDER EFFECT; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE COURSE; DYSLIPIDEMIA; ELASTOGRAPH; ENHANCED LIVER FIBROSIS SCORE; EPIDEMIOLOGICAL DATA; FATTY LIVER; FIB 4 INDEX; FIBROGENESIS; FORNS INDEX; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER FUNCTION TEST KIT; LIVER STIFFNESS; MAGNETIC RESONANCE ELASTOGRAPHY; MORBIDITY; MORPHOLOGY; MORTALITY; NON INVASIVE MEASUREMENT; PATHOGENESIS; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PROTON DENSITY FAT FRACTION; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STELLATE CELL; SYSTEMATIC REVIEW; TRANSIENT ELASTOGRAPHY; BIOPSY; BLOOD; ECHOGRAPHY; ELASTOGRAPHY; LIVER; LIVER CIRRHOSIS; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; X-RAY COMPUTED TOMOGRAPHY;

BIOMARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; FATTY LIVER; HUMANS; HYPERTENSION, PORTAL; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; PROTON MAGNETIC RESONANCE SPECTROSCOPY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 85002915538     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i45.9880     Document Type: Review

References (156)

1. Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J, Murray CJ, Naghavi M. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med 2014; 12: 145 [PMID: 25242656 DOI: 10.1186/s12916-014-0145-y]
2. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851 [PMID: 18328931 DOI: 10.1016/S0140-6736(08)60383-9]
3. World Health Organisation. Hepatitis C factsheet, 2000. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/index.html
4. World Health Organisation. Hepatitis B factsheet, 2008. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/index.html
5. Campbell TC. Correspondence re: G-S. Qian, et al., A followup study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & amp; Prev., 3: 3-10, 1994
6. C.C. Harris, Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol., Biomarkers & amp; Prev., 3: 1-2, 1994. Cancer Epidemiol Biomarkers Prev 1994; 3: 519-521 [PMID: 8000305]
7. Autrup H, Seremet T, Wakhisi J, Wasunna A. Aflatoxin exposure measured by urinary excretion of aflatoxin B1-guanine adduct and hepatitis B virus infection in areas with different liver cancer incidence in Kenya. Cancer Res 1987; 47: 3430-3433 [PMID: 3034416]
8. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
9. Friedman SL. Liver fibrosis-from bench to bedside. J Hepatol 2003; 38 Suppl 1: S38-S53 [PMID: 12591185 DOI: 10.1016/S0168-8278(02)00429-4]
10. Shyamala K, Girish HC, Murgod S. Risk of tumor cell seeding through biopsy and aspiration cytology. J Int Soc Prev Community Dent 2014; 4: 5-11 [PMID: 24818087 DOI: 10.4103/2231-0762.12 9446]
11. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36: 437-441 [PMID: 7698705 DOI: 10.1136/gut.36.3.437]
12. Thursz M, Cooke GS, Hall AJ. Hepatitis B treatment in resource poor settings: time for action. Trop Med Int Health 2010; 15: 2-4 [PMID: 19843297 DOI: 10.1111/j.1365-3156.2009.02410.x]
13. Cobbold J, Lim A, Wylezinska M, Cunningham C, Crossey M, Thomas H, Patel N, Cox J, Taylor-Robinson S. Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis. Hepatology 2006; 43: 1401-1402; author reply 1402 [PMID: 16729323 DOI: 10.1002/hep.21217]
14. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Fléjou JF, Degott C, Belghiti J, Bernades P, Valla D, Ruszniewski P, Lévy P. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001; 344: 418-423 [PMID: 11172178 DOI: 10.1056/NEJM200102083440604]
15. Iredale JP. Hepatic stellate cell behavior during resolution of liver injury. Semin Liver Dis 2001; 21: 427-436 [PMID: 11586470 DOI: 10.1055/s-2001-17557]
16. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-549 [PMID: 9691091 DOI: 10.1172/JCI1018]
17. Kweon YO, Goodman ZD, Dienstag JL, Schiff ER, Brown NA, Burchardt E, Schoonhoven R, Brenner DA, Fried MW. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol 2001; 35: 749-755 [PMID: 11738102 DOI: 10.1016/S0168-8278(01)00218-5]
18. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]
19. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
20. Niki T, Pekny M, Hellemans K, Bleser PD, Berg KV, Vaeyens F, Quartier E, Schuit F, Geerts A. Class VI intermediate filament protein nestin is induced during activation of rat hepatic stellate cells. Hepatology 1999; 29: 520-527 [PMID: 9918930 DOI: 10.1002/hep.510290232]
21. Beaussier M, Wendum D, Schiffer E, Dumont S, Rey C, Lienhart A, Housset C. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest 2007; 87: 292-303 [PMID: 17260005 DOI: 10.1038/labinvest.3700513]
22. Forbes SJ, Russo FP, Rey V, Burra P, Rugge M, Wright NA, Alison MR. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004; 126: 955-963 [PMID: 15057733 DOI: 10.1053/j.gastro.2004.02.025]
23. Sohara N, Znoyko I, Levy MT, Trojanowska M, Reuben A. Reversal of activation of human myofibroblast-like cells by culture on a basement membrane-like substrate. J Hepatol 2002; 37: 214-221 [PMID: 12127426 DOI: 10.1016/S0168-8278(02)00103-4]
24. Preaux AM, D'ortho MP, Bralet MP, Laperche Y, Mavier P. Apoptosis of human hepatic myofibroblasts promotes activation of matrix metalloproteinase-2. Hepatology 2002; 36: 615-622 [PMID: 12198653 DOI: 10.1053/jhep.2002.35279]
25. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069-11076 [PMID: 11796725 DOI: 10.1074/jbc.M111490200]
26. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657 [PMID: 12016429 DOI: 10.1053/gast.2002.33573]
27. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231 [PMID: 11961152 DOI: 10.1056/NEJMra011775]
28. Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1705-1725 [PMID: 12404245 DOI: 10.1053/gast.2002.36572]
29. Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and Prevention of Hepatic Steatosis. Gastroenterol Hepatol (N Y) 2015; 11: 167-175 [PMID: 27099587]
30. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A, Chrétien Y, Koike K, Pessayre D, Chapman J, Barba G, Bréchot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-194 [PMID: 11818366 DOI: 10.1096/fj.01-0396com]
31. Patel JH, Cobbold JF, Thomas HC, Taylor-Robinson SD. Hepatitis C and hepatic steatosis. QJM 2010; 103: 293-303 [PMID: 20139103 DOI: 10.1093/qjmed/hcp192]
32. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-832 [PMID: 9121257 DOI: 10.1016/S0140-6736(96)07642-8]
33. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45 Suppl 4: IV1-IV11 [PMID: 10485854 DOI: 10.1136/gut.45.2008. iv1]
34. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55: 569-578 [PMID: 16531536 DOI: 10.1136/gut.2005.084475]
35. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435 [PMID: 7308988 DOI: 10.1002/hep.1840010511]
36. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-699 [PMID: 7560864 DOI: 10.1016/0168-8278(95)80226-6]
37. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201]
38. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474 [PMID: 10484010 DOI: 10.1111/j.1572-0241.1999.01377.x]
39. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321 [PMID: 15915461 DOI: 10.1002/hep.20701]
40. Paradis V, Kollinger M, Fabre M, Holstege A, Poynard T, Bedossa P. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology 1997; 26: 135-142 [PMID: 9214462 DOI: 10.1002/hep.510260118]
41. Lindor KD, Bru C, Jorgensen RA, Rakela J, Bordas JM, Gross JB, Rodes J, McGill DB, Reading CC, James EM, Charboneau JW, Ludwig J, Batts KP, Zinsmeister AR. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083 [PMID: 8621137 DOI: 10.1002/hep.510230522]
42. Perrault J, McGill DB, Ott BJ, Taylor WF. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74: 103-106 [PMID: 618417]
43. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481 [PMID: 10960438 DOI: 10.1053/jhep.2000.16602]
44. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and metaanalysis. Gut 2008; 57: 1592-1596 [PMID: 18669577 DOI: 10.1136/gut.2008.149062]
45. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457 [PMID: 14647056 DOI: 10.1016/j.hep.2003.09.022]
46. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525 [PMID: 2869260 DOI: 10.1016/S0140-6736(86)90883-4]
47. Poniachik J, Bernstein DE, Reddy KR, Jeffers LJ, Coelho-Little ME, Civantos F, Schiff ER. The role of laparoscopy in the diagnosis of cirrhosis. Gastrointest Endosc 1996; 43: 568-571 [PMID: 8781934 DOI: 10.1016/S0016-5107(96)70192-X]
48. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR, Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618 [PMID: 12385448 DOI: 10.1111/j.1572-0241.2002.06038.x]
49. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-244 [PMID: 12873821 DOI: 10.1016/S0168-8278(03)00191-0]
50. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, Patel N. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25: 649-654 [PMID: 8938541 DOI: 10.1016/S0168-8278(96)80234-0]
51. Rousselet MC, Michalak S, Dupré F, Croué A, Bedossa P, Saint-André JP, Calès P. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-264 [PMID: 15660389 DOI: 10.1002/hep.20535]
52. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006; 44: 462-474 [PMID: 16427156 DOI: 10.1016/j.jhep.2005.10.019]
53. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113-S120 [PMID: 16447288 DOI: 10.1002/hep.21046]
54. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007; 46: 912-921 [PMID: 17705266 DOI: 10.1002/hep.21835]
55. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134: 1670-1681 [PMID: 18471546 DOI: 10.1053/j.gastro.2008.03.001]
56. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526 [PMID: 12883497 DOI: 10.1053/jhep.2003.50346]
57. Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, Sun Y, Xuan SY. Performance of the aspartate aminotransferase-toplatelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736 [PMID: 21319189 DOI: 10.1002/hep.24105]
58. Borsoi Viana MS, Takei K, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009; 8: 26-31 [PMID: 19221530]
59. Catanzaro R, Milazzo M, Arona S, Sapienza C, Vasta D, Arcoria D, Marotta F. Diagnostic accuracy of enhanced liver fibrosis test to assess liver fibrosis in patients with chronic hepatitis C. Hepatobiliary Pancreat Dis Int 2013; 12: 500-507 [PMID: 24103280 DOI: 10.1016/S1499-3872(13)60079-X]
60. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713 [PMID: 15578508 DOI: 10.1053/j.gastro.2004.08.052]
61. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59: 236-242 [PMID: 23523583 DOI: 10.1016/j.jhep.2013.03.016]
62. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Metaanalyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40 [PMID: 17937811 DOI: 10.1186/1471-230X-7-40]
63. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection.comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32-36 [PMID: 17567829 DOI: 10.1002/hep.21669]
64. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-992 [PMID: 12297848 DOI: 10.1053/jhep.2002.36128]
65. Güzelbulut F, Çetinkaya ZA, Sezikli M, Yaşar B, Ozkara S, Övünç AO. AST-platelet ratio index, Forns index and FIB-4 in the prediction of significant fibrosis and cirrhosis in patients with chronic hepatitis C. Turk J Gastroenterol 2011; 22: 279-285 [PMID: 21805418]
66. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713 [PMID: 14698338 DOI: 10.1016/j.ultrasmedbio.2003.07.001]
67. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54 [PMID: 15690481 DOI: 10.1002/hep.20506]
68. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659 [PMID: 21146892 DOI: 10.1016/j.jhep.2010.07.033]
69. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974 [PMID: 18395077 DOI: 10.1053/j.gastro.2008.01.034]
70. Trovato FM, Tognarelli JM, Crossey MM, Catalano D, Taylor-Robinson SD, Trovato GM. Challenges of liver cancer: Future emerging tools in imaging and urinary biomarkers. World J Hepatol 2015; 7: 2664-2675 [PMID: 26609343 DOI: 10.4254/wjh. v7.i26.2664]
71. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20 [PMID: 21920839 DOI: 10.1016/j.clinre.2011.08.001]
72. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, Poupon R, Cardoso AC, Marcellin P, Douvin C, de Ledinghen V, Trinchet JC, Beaugrand M. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(®): validation in chronic hepatitis C. J Viral Hepat 2012; 19: 244-253 [PMID: 22404722 DOI: 10.1111/j.1365-2893.2011.01534.x]
73. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, Zeuzem S, Bojunga J. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-e331 [PMID: 22119555 DOI: 10.1016/j.ejrad.2011.10.029]
74. Friedrich-Rust M, Nierhoff J, Lupsor M, Sporea I, Fierbinteanu-Braticevici C, Strobel D, Takahashi H, Yoneda M, Suda T, Zeuzem S, Herrmann E. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-e219 [PMID: 22239521 DOI: 10.1111/j.1365-2893.2011.01537.x]
75. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, Peck-Radosavljevic M. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33: 1138-1147 [PMID: 23859217 DOI: 10.1111/liv.12240]
76. Sporea I, Bota S, Grǎdinaru-Taşcǎu O, Şirli R, Popescu A. Comparative study between two point Shear Wave Elastographic techniques: Acoustic Radiation Force Impulse (ARFI) elastography and ElastPQ. Med Ultrason 2014; 16: 309-314 [PMID: 25463883]
77. Ma JJ, Ding H, Mao F, Sun HC, Xu C, Wang WP. Assessment of liver fibrosis with elastography point quantification technique in chronic hepatitis B virus patients: a comparison with liver pathological results. J Gastroenterol Hepatol 2014; 29: 814-819 [PMID: 24325607 DOI: 10.1111/jgh.12479]
78. Grier S, Lim AK, Patel N, Cobbold JF, Thomas HC, Cox IJ, Taylor-Robinson SD. Role of microbubble ultrasound contrast agents in the non-invasive assessment of chronic hepatitis C-related liver disease. World J Gastroenterol 2006; 12: 3461-3465 [PMID: 16773702 DOI: 10.3748/wjg.v12.i22.3461]
79. Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, Oren R. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR Am J Roentgenol 2009; 192: 909-914 [PMID: 19304694 DOI: 10.2214/AJR.07.4016]
80. Mehta SR, Thomas EL, Bell JD, Johnston DG, Taylor-Robinson SD. Non-invasive means of measuring hepatic fat content. World J Gastroenterol 2008; 14: 3476-3483 [PMID: 18567074 DOI: 10.3748/wjg.14.3476]
81. Ryan CK, Johnson LA, Germin BI, Marcos A. One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl 2002; 8: 1114-1122 [PMID: 12474149 DOI: 10.1053/jlts.2002.36740]
82. Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR. Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 2005; 39: 619-625 [PMID: 16000931 DOI: 10.1097/00004836-200 508000-00012]
83. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N. Noninvasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999; 353: 1579-1583 [PMID: 10334257 DOI: 10.1016/S0140-6736(98)06373-9]
84. Lim AK, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC, Cosgrove DO, Blomley MJ. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133 [PMID: 15591518 DOI: 10.1136/gut.2003.030965]
85. Bydder GM, Kreel L, Chapman RW, Harry D, Sherlock S, Bassan L. Accuracy of computed tomography in diagnosis of fatty liver. Br Med J 1980; 281: 1042 [PMID: 7427567]
86. Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, Ha HK, Lee MG, Hwang S, Lee SG, Yu ES, Cho EY. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006; 239: 105-112 [PMID: 16484355 DOI: 10.1148/radiol.2391050361]
87. Pavlides M, Banerjee R, Sellwood J, Kelly CJ, Robson MD, Booth JC, Collier J, Neubauer S, Barnes E. Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 2016; 64: 308-315 [PMID: 26471505 DOI: 10.1016/j.jhep.2015.10.009]
88. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging 2007; 26: 1081-1086 [PMID: 17896383 DOI: 10.1002/jmri.21119]
89. Banerjee R, Pavlides M, Tunnicliffe EM, Piechnik SK, Sarania N, Philips R, Collier JD, Booth JC, Schneider JE, Wang LM, Delaney DW, Fleming KA, Robson MD, Barnes E, Neubauer S. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 2014; 60: 69-77 [PMID: 24036007 DOI: 10.1016/j.jhep.2013.09.002]
90. Cassinotto C, Feldis M, Vergniol J, Mouries A, Cochet H, Lapuyade B, Hocquelet A, Juanola E, Foucher J, Laurent F, De Ledinghen V. MR relaxometry in chronic liver diseases: Comparison of T1 mapping, T2 mapping, and diffusion-weighted imaging for assessing cirrhosis diagnosis and severity. Eur J Radiol 2015; 84: 1459-1465 [PMID: 26032126 DOI: 10.1016/j.ejrad.2015.05.019]
91. Low G, Kruse SA, Lomas DJ. General review of magnetic resonance elastography. World J Radiol 2016; 8: 59-72 [PMID: DOI: 10.4329/wjr.v8.i1.59]
92. Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol 2015; 13: 440-451.e6 [PMID: 25305349 DOI: 10.1016/j.cgh.2014.09.046]
93. Su LN, Guo SL, Li BX, Yang P. Diagnostic value of magnetic resonance elastography for detecting and staging of hepatic fibrosis: a meta-analysis. Clin Radiol 2014; 69: e545-e552 [PMID: 25300557 DOI: 10.1016/j.crad.2014.09.001]
94. Lee VS, Miller FH, Omary RA, Wang Y, Ganger DR, Wang E, Rao S, Levitsky J. Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation 2011; 92: 581-586 [PMID: 21822174 DOI: 10.1097/TP.0b013e31822805fa]
95. Bohte AE, de Niet A, Jansen L, Bipat S, Nederveen AJ, Verheij J, Terpstra V, Sinkus R, van Nieuwkerk KM, de Knegt RJ, Baak BC, Jansen PL, Reesink HW, Stoker J. Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol 2014; 24: 638-648 [PMID: 24158528 DOI: 10.1007/s00330-013-3046-0]
96. Takamura T, Motosugi U, Ichikawa S, Sano K, Morisaka H, Ichikawa T, Enomoto N, Onishi H. Usefulness of MR elastography for detecting clinical progression of cirrhosis from child-pugh class A to B in patients with type C viral hepatitis. J Magn Reson Imaging 2016; 44: 715-722 [PMID: 26929192 DOI: 10.1002/jmri.25182]
97. Taouli B, Serfaty L. Magnetic Resonance Imaging/Elastography Is Superior to Transient Elastography for Detection of Liver Fibrosis and Fat in Nonalcoholic Fatty Liver Disease. Gastroenterology 2016; 150: 553-556 [PMID: 26820053 DOI: 10.1053/j.gastro.2016.01.017]
98. Shi Y, Xia F, Li QJ, Li JH, Yu B, Li Y, An H, Glaser KJ, Tao S, Ehman RL, Guo QY. Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study. Am J Gastroenterol 2016; 111: 823-833 [PMID: 26977760 DOI: 10.1038/ajg.2016.56]
99. Loomba R, Cui J, Wolfson T, Haufe W, Hooker J, Szeverenyi N, Ang B, Bhatt A, Wang K, Aryafar H, Behling C, Valasek MA, Lin GY, Gamst A, Brenner DA, Yin M, Glaser KJ, Ehman RL, Sirlin CB. Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study. Am J Gastroenterol 2016; 111: 986-994 [PMID: 27002798 DOI: 10.1038/ajg.2016.65]
100. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Crocè LS, Grigolato P, Paoletti S, de Bernard B. Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis. J Magn Reson Imaging 1995; 5: 281-285 [PMID: 7633104 DOI: 10.1002/jmri.1880050311]
101. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI: 10.1002/hep.20466]
102. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005; 288: E462-E468 [PMID: 15339742 DOI: 10.1152/ajpendo.00064.2004]
103. Thomas EL, Hamilton G, Patel N, O'Dwyer R, Doré CJ, Goldin RD, Bell JD, Taylor-Robinson SD. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 2005; 54: 122-127 [PMID: 15591516 DOI: 10.1136/gut.2003.036566]
104. Thomas EL, Brynes AE, Hamilton G, Patel N, Spong A, Goldin RD, Frost G, Bell JD, Taylor-Robinson SD. Effect of nutritional counselling on hepatic, muscle and adipose tissue fat content and distribution in non-alcoholic fatty liver disease. World J Gastroenterol 2006; 12: 5813-5819 [PMID: 17007047 DOI: 10.3748/wjg.v12.i36.5813]
105. Otten J, Mellberg C, Ryberg M, Sandberg S, Kullberg J, Lindahl B, Larsson C, Hauksson J, Olsson T. Strong and persistent effect on liver fat with a Paleolithic diet during a two-year intervention. Int J Obes (Lond) 2016; 40: 747-753 [PMID: 26786351 DOI: 10.1038/ijo.2016.4]
106. Chiang HJ, Lin LH, Li CW, Lin CC, Chiang HW, Huang TL, Chen CL, Cheng YF. Magnetic resonance fat quantification in living donor liver transplantation. Transplant Proc 2014; 46: 666-668 [PMID: 24767318 DOI: 10.1016/j.transproceed.2015.10.0 68]
107. Lui G, Wong VW, Wong GL, Chu WC, Wong CK, Yung IM, Wong RY, Yeung SL, Yeung DK, Cheung CS, Chan HY, Chan HL, Lee N. Liver fibrosis and fatty liver in Asian HIV-infected patients. Aliment Pharmacol Ther 2016; 44: 411-421 [PMID: 27301337 DOI: 10.1111/apt.13702]
108. Reeder SB, Hu HH, Sirlin CB. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration. J Magn Reson Imaging 2012; 36: 1011-1014 [PMID: 22777847 DOI: 10.1002/jmri.23741]
109. Idilman IS, Keskin O, Celik A, Savas B, Halil Elhan A, Idilman R, Karcaaltincaba M. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease. Acta Radiol 2016; 57: 271-278 [PMID: 25855666 DOI: 10.1177/0 284185115580488]
110. Bashir MR, Zhong X, Nickel MD, Fananapazir G, Kannengiesser SA, Kiefer B, Dale BM. Quantification of hepatic steatosis with a multistep adaptive fitting MRI approach: prospective validation against MR spectroscopy. AJR Am J Roentgenol 2015; 204: 297-306 [PMID: 25615751 DOI: 10.2214/AJR.14.12457]
111. Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, Clark L, Hooker J, Chavez T, Ang BD, Middleton MS, Peterson M, Loomba R, Sirlin CB. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 2015; 274: 416-425 [PMID: 25247408 DOI: 10.1148/radiol.14140754]
112. Horng DE, Hernando D, Reeder SB. Quantification of liver fat in the presence of iron overload. J Magn Reson Imaging 2016; Epub ahead of print [PMID: 27405703 DOI: 10.1002/jmri.25382]
113. Paparo F, Cenderello G, Revelli M, Bacigalupo L, Rutigliani M, Zefiro D, Cevasco L, Amico M, Bandelloni R, Cassola G, Forni GL, Rollandi GA. Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. Biomed Res Int 2015; 2015: 758164 [PMID: 25866807 DOI: 10.1155/2015/758164]
114. Heba ER, Desai A, Zand KA, Hamilton G, Wolfson T, Schlein AN, Gamst A, Loomba R, Sirlin CB, Middleton MS. Accuracy and the effect of possible subject-based confounders of magnitude-based MRI for estimating hepatic proton density fat fraction in adults, using MR spectroscopy as reference. J Magn Reson Imaging 2016; 43: 398-406 [PMID: 26201284 DOI: 10.1002/jmri.25006]
115. Bell JD, Cox IJ, Sargentoni J, Peden CJ, Menon DK, Foster CS, Watanapa P, Iles RA, Urenjak J. A 31P and 1H-NMR investigation in vitro of normal and abnormal human liver. Biochim Biophys Acta 1993; 1225: 71-77 [PMID: 8241291 DOI: 10.1016/0925-443 9(93)90124-J]
116. Taylor-Robinson SD, Thomas EL, Sargentoni J, Marcus CD, Davidson BR, Bell JD. Cirrhosis of the human liver: an in vitro 31P nuclear magnetic resonance study. Biochim Biophys Acta 1995; 1272: 113-118 [PMID: 7548234 DOI: 10.1016/0925-4439(9 5)00074-E]
117. Lim AK, Patel N, Hamilton G, Hajnal JV, Goldin RD, Taylor-Robinson SD. The relationship of in vivo 31P MR spectroscopy to histology in chronic hepatitis C. Hepatology 2003; 37: 788-794 [PMID: 12668971 DOI: 10.1053/jhep.2003.50149]
118. Menon DK, Sargentoni J, Taylor-Robinson SD, Bell JD, Cox IJ, Bryant DJ, Coutts GA, Rolles K, Burroughs AK, Morgan MY. Effect of functional grade and etiology on in vivo hepatic phosphorus-31 magnetic resonance spectroscopy in cirrhosis: biochemical basis of spectral appearances. Hepatology 1995; 21: 417-427 [PMID: 7843715 DOI: 10.1016/0270-9139(95)90102-7]
119. Yamane Y, Umeda M, O'uchi T, Mitsushima T, Nakata K, Nagataki S. Phosphorus-31 nuclear magnetic resonance in vivo spectroscopy of human liver during hepatitis A virus infection. Dig Dis Sci 1994; 39: 33-38 [PMID: 8281864 DOI: 10.1007/BF02090057]
120. Lim AK, Patel N, Hamilton G, Mylvahan K, Kuo YT, Goldin RD, Taylor-Robinson SD. 31P MR spectroscopy in assessment of response to antiviral therapy for hepatitis C virus-related liver disease. AJR Am J Roentgenol 2007; 189: 819-823 [PMID: 17885051 DOI: 10.2214/AJR.07.2418]
121. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 92-104 [PMID: 22035045 DOI: 10.1111/j.1365-2036.2011.04897.x]
122. Castéra L, Sebastiani G, Le Bail B, de Lédinghen V, Couzigou P, Alberti A. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198 [PMID: 20006397 DOI: 10.1016/j.jhep.2009.11.008]
123. Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N, Rousselet MC, Konaté A, Amrani N, de Ledinghen V, Calès P. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int 2009; 29: 1507-1515 [PMID: 19725892 DOI: 10.1111/j.1478-3231.2009.02101.x]
124. Harman DJ, Ryder SD, James MW, Jelpke M, Ottey DS, Wilkes EA, Card TR, Aithal GP, Guha IN. Direct targeting of risk factors significantly increases the detection of liver cirrhosis in primary care: a cross-sectional diagnostic study utilising transient elastography. BMJ Open 2015; 5: e007516 [PMID: 25941185 DOI: 10.1136/bmjopen-2014-007516]
125. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D. Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003; 227: 89-94 [PMID: 12601199 DOI: 10.1148/radiol.2272020193]
126. Aubé C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Rifflet H, Mäga MY, Penneau-Fontbonne D, Caron C, Calès P. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 472-478 [PMID: 10190731 DOI: 10.1016/S0168-8278(99)80107-X]
127. Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002; 224: 769-774 [PMID: 12202712 DOI: 10.1148/radiol.2243011495]
128. Ito K, Mitchell DG, Hann HW, Kim Y, Fujita T, Okazaki H, Honjo K, Matsunaga N. Viral-induced cirrhosis: grading of severity using MR imaging. AJR Am J Roentgenol 1999; 173: 591-596 [PMID: 10470885 DOI: 10.2214/ajr.173.3.10470885]
129. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast materialenhanced MR imaging. Radiology 2006; 239: 425-437 [PMID: 16641352 DOI: 10.1148/radiol.2392050505]
130. Romero-Gómez M, Gómez-González E, Madrazo A, Vera-Valencia M, Rodrigo L, Pérez-Alvarez R, Pérez-López R, Castellano-Megias VM, Nevado-Santos M, Alcón JC, Solá R, Pérez-Moreno JM, Navarro JM, Andrade RJ, Salmerón J, Fernández-López M, Aznar R, Diago M. Optical analysis of computed tomography images of the liver predicts fibrosis stage and distribution in chronic hepatitis C. Hepatology 2008; 47: 810-816 [PMID: 18098299 DOI: 10.1002/hep.22112]
131. Aubé C, Racineux PX, Lebigot J, Oberti F, Croquet V, Argaud C, Calès P, Caron C. [Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results]. J Radiol 2004; 85: 301-306 [PMID: 15192522 DOI: 10.1016/S0221-0363(04)97582-8]
132. Lewin M, Poujol-Robert A, Boëlle PY, Wendum D, Lasnier E, Viallon M, Guéchot J, Hoeffel C, Arrivé L, Tubiana JM, Poupon R. Diffusion-weighted magnetic resonance imaging for the assessment of fibrosis in chronic hepatitis C. Hepatology 2007; 46: 658-665 [PMID: 17663420 DOI: 10.1002/hep.21747]
133. Taouli B, Tolia AJ, Losada M, Babb JS, Chan ES, Bannan MA, Tobias H. Diffusion-weighted MRI for quantification of liver fibrosis: preliminary experience. AJR Am J Roentgenol 2007; 189: 799-806 [PMID: 17885048 DOI: 10.2214/AJR.07.2086]
134. Langer DA, Shah VH. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis. J Hepatol 2006; 44: 209-216 [PMID: 16297493 DOI: 10.1016/j.jhep.2005.10.004]
135. Vilgrain V. Ultrasound of diffuse liver disease and portal hypertension. Eur Radiol 2001; 11: 1563-1577 [PMID: 11511876 DOI: 10.1007/s003300101050]
136. Bernatik T, Strobel D, Hahn EG, Becker D. Doppler measurements: a surrogate marker of liver fibrosis? Eur J Gastroenterol Hepatol 2002; 14: 383-387 [PMID: 11943950]
137. Lim AK, Patel N, Eckersley RJ, Kuo YT, Goldin RD, Thomas HC, Cosgrove DO, Taylor-Robinson SD, Blomley MJ. Can Doppler sonography grade the severity of hepatitis C-related liver disease? AJR Am J Roentgenol 2005; 184: 1848-1853 [PMID: 15908541 DOI: 10.2214/ajr.184.6.01841848]
138. Foucher J, Chanteloup E, Vergniol J, Castéra L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Lédinghen V. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55: 403-408 [PMID: 16020491 DOI: 10.1136/gut.2005.069153]
139. Kazemi F, Kettaneh A, N'kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, Beaugrand M. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol 2006; 45: 230-235 [PMID: 16797100 DOI: 10.1016/j.jhep.2006.04.006]
140. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, Marra F, Laffi G, Pinzani M. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45: 1290-1297 [PMID: 17464971 DOI: 10.1002/hep.21665]
141. Lim JK, Groszmann RJ. Transient elastography for diagnosis of portal hypertension in liver cirrhosis: is there still a role for hepatic venous pressure gradient measurement? Hepatology 2007; 45: 1087-1090 [PMID: 17464984 DOI: 10.1002/hep.21731]
142. Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology 1995; 21: 1238-1247 [PMID: 7737629 DOI: 10.1016/0270-9139(95)90043-8]
143. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007; 45: 817-825 [PMID: 17326208 DOI: 10.1002/hep.21564]
144. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007; 56: 968-973 [PMID: 17255218 DOI: 10.1136/gut.2006.111302]
145. Coco B, Oliveri F, Maina AM, Ciccorossi P, Sacco R, Colombatto P, Bonino F, Brunetto MR. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-369 [PMID: 17439526 DOI: 10.1111/j.1365-2893.2006.00811.x]
146. Arena U, Vizzutti F, Corti G, Ambu S, Stasi C, Bresci S, Moscarella S, Boddi V, Petrarca A, Laffi G, Marra F, Pinzani M. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-384 [PMID: 18095306 DOI: 10.1002/hep.22007]
147. Sagir A, Erhardt A, Schmitt M, Häussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008; 47: 592-595 [PMID: 18098325 DOI: 10.1002/hep.22056]
148. Cobbold JF, Taylor-Robinson SD. Transient elastography in acute hepatitis: All that's stiff is not fibrosis. Hepatology 2008; 47: 370-372 [PMID: 18220278 DOI: 10.1002/hep.22200]
149. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350 [PMID: 15685546 DOI: 10.1053/j.gastro.2004.11.018]
150. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouillères O, de Lédinghen V, Dhumeaux D, Marcellin P, Beaugrand M, Poupon R. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006; 43: 1118-1124 [PMID: 16628644 DOI: 10.1002/hep.21151]
151. Ganne-Carrié N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet JC, Beaugrand M. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006; 44: 1511-1517 [PMID: 17133503 DOI: 10.1002/hep.21420]
152. Yoneda M, Yoneda M, Fujita K, Inamori M, Tamano M, Hiriishi H, Nakajima A. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56: 1330-1331 [PMID: 17470477 DOI: 10.1136/gut.2007.126417]
153. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-847 [PMID: 18334275 DOI: 10.1016/j.jhep.2008.02.008]
154. Yeh WC, Li PC, Jeng YM, Hsu HC, Kuo PL, Li ML, Yang PM, Lee PH. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol 2002; 28: 467-474 [PMID: 12049960 DOI: 10.1016/S0301-5629(02)00489-1]
155. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-613 [PMID: 18222014 DOI: 10.1016/j.jhep.2007.11.020]
156. Dowman JK, Tomlinson JW, Newsome PN. Pathogenesis of non-alcoholic fatty liver disease. QJM 2010; 103: 71-83 [PMID: 19914930 DOI: 10.1093/qjmed/hcp158]